Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc.
Cells
; 9(4)2020 04 04.
Article
em En
| MEDLINE
| ID: mdl-32260326
ABSTRACT
First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. The recently described therapeutic effect of purified Omomyc mini-protein-following the surprising discovery of its cell-penetrating capacity-constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fragmentos de Peptídeos
/
Proteínas Proto-Oncogênicas c-myc
/
Neoplasias
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article